257 related articles for article (PubMed ID: 21618503)
21. [Immunology: new approaches to immuno-modulation and immunotherapy].
Kabelitz D
Dtsch Med Wochenschr; 2006 Jun; 131(25-26):1471-3. PubMed ID: 16794979
[No Abstract] [Full Text] [Related]
22. Human tumour-associated antigens: targets for monoclonal antibody-mediated cancer therapy.
Reisfeld RA; Cheresh DA
Cancer Surv; 1985; 4(1):271-90. PubMed ID: 3916082
[No Abstract] [Full Text] [Related]
23. T cell-based immunotherapy for cancer: a virtual reality?
Lum LG
CA Cancer J Clin; 1999; 49(2):74-100, 65. PubMed ID: 11198889
[TBL] [Abstract][Full Text] [Related]
24. Genetically engineered T cells for the treatment of cancer.
Essand M; Loskog AS
J Intern Med; 2013 Feb; 273(2):166-81. PubMed ID: 23198862
[TBL] [Abstract][Full Text] [Related]
25. T-cell chauvinists versus antibody advocates--can't we all just get along?
Chapman PB
J Clin Oncol; 2004 Nov; 22(22):4446-8. PubMed ID: 15483013
[No Abstract] [Full Text] [Related]
26. Genetic redirection of T cells for cancer therapy.
Westwood JA; Kershaw MH
J Leukoc Biol; 2010 May; 87(5):791-803. PubMed ID: 20179152
[TBL] [Abstract][Full Text] [Related]
27. Immunoreceptor Engineering and Synthetic Cytokine Signaling for Therapeutics.
Scheller J; Engelowski E; Moll JM; Floss DM
Trends Immunol; 2019 Mar; 40(3):258-272. PubMed ID: 30738638
[TBL] [Abstract][Full Text] [Related]
28. Advances in cancer immunotherapy.
Ockert D; Schmitz M; Hampl M; Rieber EP
Immunol Today; 1999 Feb; 20(2):63-5. PubMed ID: 10098323
[No Abstract] [Full Text] [Related]
29. CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
Miliotou AN; Papadopoulou LC
Curr Pharm Biotechnol; 2018; 19(1):5-18. PubMed ID: 29667553
[TBL] [Abstract][Full Text] [Related]
30. Making cancer immunotherapy a surer bet.
Eisenstein M
Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
[No Abstract] [Full Text] [Related]
31. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects.
Kalos M
Vaccine; 2003 Jan; 21(7-8):781-6. PubMed ID: 12531359
[TBL] [Abstract][Full Text] [Related]
32. The present status and future prospects of peptide-based cancer vaccines.
Hirayama M; Nishimura Y
Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
[TBL] [Abstract][Full Text] [Related]
33. [Monoclonal antibodies and cancer].
López González JS; Selman Lama M
Salud Publica Mex; 1985; 27(3):213-34. PubMed ID: 2996157
[No Abstract] [Full Text] [Related]
34. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy: a treatment for the masses.
Blattman JN; Greenberg PD
Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
[TBL] [Abstract][Full Text] [Related]
36. Target cell induced T cell activation with bispecific antibodies: a new concept for tumor immunotherapy.
Wolf H; Freimann U; Jung G
Recent Results Cancer Res; 1994; 135():185-95. PubMed ID: 8047693
[No Abstract] [Full Text] [Related]
37. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.
Yee C; Greenberg P
Nat Rev Cancer; 2002 Jun; 2(6):409-19. PubMed ID: 12189383
[No Abstract] [Full Text] [Related]
38. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
39. Targeting tumours with genetically enhanced T lymphocytes.
Sadelain M; Rivière I; Brentjens R
Nat Rev Cancer; 2003 Jan; 3(1):35-45. PubMed ID: 12509765
[TBL] [Abstract][Full Text] [Related]
40. Beyond ipilimumab: new approaches target the immunological synapse.
Garber K
J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
